Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have changed considerably the management of type 2 diabetes (T2D). However, recently published data from retrospective cohort studies suggest that chronic exposure to GLP-1RAs in T2D may increase the risk of papillary and medullary thyroid cancer....

Full description

Saved in:
Bibliographic Details
Published inEndocrine Connections Vol. 12; no. 11; pp. 1 - 7
Main Authors Lisco, Giuseppe, De Tullio, Anna, Disoteo, Olga, Piazzolla, Giuseppina, Guastamacchia, Edoardo, Sabbà, Carlo, De Geronimo, Vincenzo, Papini, Enrico, Triggiani, Vincenzo
Format Journal Article
LanguageEnglish
Published Bristol Bioscientifica Ltd 01.11.2023
Bioscientifica
Subjects
dipeptidyl peptidase iv
glucagon-like peptide 1 receptor agonist
incretin system
medullary thyroid cancer
papillary thyroid cancer
Review
medullary thyroid cancer
dipeptidyl peptidase IV
incretin system
papillary thyroid cancer
glucagon-like peptide 1 receptor agonist
Online AccessGet full text

Cover

Abstract Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have changed considerably the management of type 2 diabetes (T2D). However, recently published data from retrospective cohort studies suggest that chronic exposure to GLP-1RAs in T2D may increase the risk of papillary and medullary thyroid cancer. In this perspective, the role of the incretin system in thyroid carcinogenesis has been reviewed and critically commented on, aiming to understand if the time has arrived to be concerned about the risk. Although evidence suggested, speculative hypotheses should be verified, and further studies are urgently needed to clarify the issue.
AbstractList Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have changed considerably the management of type 2 diabetes (T2D). However, recently published data from retrospective cohort studies suggest that chronic exposure to GLP-1RAs in T2D may increase the risk of papillary and medullary thyroid cancer. In this perspective, the role of the incretin system in thyroid carcinogenesis has been reviewed and critically commented on, aiming to understand if the time has arrived to be concerned about the risk. Although evidence suggested, speculative hypotheses should be verified, and further studies are urgently needed to clarify the issue.
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have changed considerably the management of type 2 diabetes (T2D). However, recently published data from retrospective cohort studies suggest that chronic exposure to GLP-1RAs in T2D may increase the risk of papillary and medullary thyroid cancer. In this perspective, the role of the incretin system in thyroid carcinogenesis has been reviewed and critically commented on, aiming to understand if the time has arrived to be concerned about the risk. Although evidence suggested, speculative hypotheses should be verified, and further studies are urgently needed to clarify the issue.Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have changed considerably the management of type 2 diabetes (T2D). However, recently published data from retrospective cohort studies suggest that chronic exposure to GLP-1RAs in T2D may increase the risk of papillary and medullary thyroid cancer. In this perspective, the role of the incretin system in thyroid carcinogenesis has been reviewed and critically commented on, aiming to understand if the time has arrived to be concerned about the risk. Although evidence suggested, speculative hypotheses should be verified, and further studies are urgently needed to clarify the issue.
Author De Tullio, Anna
Disoteo, Olga
Papini, Enrico
Triggiani, Vincenzo
Sabbà, Carlo
De Geronimo, Vincenzo
Guastamacchia, Edoardo
Lisco, Giuseppe
Piazzolla, Giuseppina
AuthorAffiliation Diabetology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
Department of Endocrinology and Metabolism, Regina Apostolorum Hospital, Rome, Italy
Unit of Endocrinology, Policlinico Morgagni CCD, Catania, Italy
Interdisciplinary Department of Medicine, Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases, School of Medicine, University of Bari “Aldo Moro”, Piazza Giulio Cesare, Bari, Italy
AuthorAffiliation_xml – name: Department of Endocrinology and Metabolism, Regina Apostolorum Hospital, Rome, Italy
– name: Unit of Endocrinology, Policlinico Morgagni CCD, Catania, Italy
– name: Interdisciplinary Department of Medicine, Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases, School of Medicine, University of Bari “Aldo Moro”, Piazza Giulio Cesare, Bari, Italy
– name: Diabetology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
Author_xml – sequence: 1
  givenname: Giuseppe
  orcidid: 0000-0001-6521-8578
  surname: Lisco
  fullname: Lisco, Giuseppe
  email: giuseppe.lisco@uniba.it
  organization: Interdisciplinary Department of Medicine, Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases, School of Medicine, University of Bari “Aldo Moro”, Piazza Giulio Cesare, Bari, Italy
– sequence: 2
  givenname: Anna
  surname: De Tullio
  fullname: De Tullio, Anna
  organization: Interdisciplinary Department of Medicine, Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases, School of Medicine, University of Bari “Aldo Moro”, Piazza Giulio Cesare, Bari, Italy
– sequence: 3
  givenname: Olga
  surname: Disoteo
  fullname: Disoteo, Olga
  organization: Diabetology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
– sequence: 4
  givenname: Giuseppina
  surname: Piazzolla
  fullname: Piazzolla, Giuseppina
  organization: Interdisciplinary Department of Medicine, Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases, School of Medicine, University of Bari “Aldo Moro”, Piazza Giulio Cesare, Bari, Italy
– sequence: 5
  givenname: Edoardo
  surname: Guastamacchia
  fullname: Guastamacchia, Edoardo
  organization: Interdisciplinary Department of Medicine, Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases, School of Medicine, University of Bari “Aldo Moro”, Piazza Giulio Cesare, Bari, Italy
– sequence: 6
  givenname: Carlo
  surname: Sabbà
  fullname: Sabbà, Carlo
  organization: Interdisciplinary Department of Medicine, Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases, School of Medicine, University of Bari “Aldo Moro”, Piazza Giulio Cesare, Bari, Italy
– sequence: 7
  givenname: Vincenzo
  surname: De Geronimo
  fullname: De Geronimo, Vincenzo
  organization: Unit of Endocrinology, Policlinico Morgagni CCD, Catania, Italy
– sequence: 8
  givenname: Enrico
  surname: Papini
  fullname: Papini, Enrico
  organization: Department of Endocrinology and Metabolism, Regina Apostolorum Hospital, Rome, Italy
– sequence: 9
  givenname: Vincenzo
  surname: Triggiani
  fullname: Triggiani, Vincenzo
  organization: Interdisciplinary Department of Medicine, Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases, School of Medicine, University of Bari “Aldo Moro”, Piazza Giulio Cesare, Bari, Italy
BookMark eNp9kU2LFDEQhoOsuB_uxV-Qowi9Jp1O0vGyyDCuCwte9CghH5XZrD2dMckI--9NOyO4IuaQVOqt96mCOkcnc5oBoVeUXFHOyNv1qutZR3oun6GzngyqY4IOJ3_Ep-iylAfSzkjFyMgLdMqk4IITdYa-3kx7ZzZp7qb4DfAOdjV6wBRncC1OGS9iLLVgM3tc7x9zih47MzvI73AsONaWBVzjtl0JW8AuLeIM_voleh7MVODy-F6gLx_Wn1cfu7tPN7er93edHQSrnREjkYFKBZYzwSjxyg2eKcWClEClHBUDSg0PdAAbhOXt149E8DFQYxS7QLcHrk_mQe9y3Jr8qJOJ-lci5Y02uUY3gbbe8cFRL6ixA6hguZdUEi4s831wY2NdH1i7vd2CdzDXbKYn0KfKHO_1Jv3QtEGYIH0jvD4Scvq-h1L1NhYH02RmSPui-1GQgVDOl2bkUOpyKiVD0C5WU2Na0HFqTL1sWa9Xumd62XKzvPnL8nu0fxYf-Tam4mKbOIbozP8sPwHzM7dP
CitedBy_id crossref_primary_10_1016_S2213_8587_24_00200_6
crossref_primary_10_1007_s40618_024_02466_4
crossref_primary_10_1055_a_2374_8756
crossref_primary_10_1001_jama_2024_5998
crossref_primary_10_1111_dom_15869
crossref_primary_10_3390_biom14111479
crossref_primary_10_1007_s00464_024_11191_1
crossref_primary_10_7326_ANNALS_24_01590
crossref_primary_10_1016_j_cpcardiol_2025_103036
crossref_primary_10_1097_MD_0000000000040364
crossref_primary_10_3390_endocrines5030023
crossref_primary_10_1016_j_euo_2024_04_006
crossref_primary_10_36303_SAPJ_2299
crossref_primary_10_3390_cancers16091625
ContentType Journal Article
Copyright the author(s)
the author(s) 2023 the author(s)
Copyright_xml – notice: the author(s)
– notice: the author(s) 2023 the author(s)
DBID AAYXX
CITATION
7X8
5PM
DOA
DOI 10.1530/EC-23-0257
DatabaseName CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList

CrossRef

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals (DOAJ)
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
DocumentTitleAlternate G Lisco et al
EISSN 2049-3614
EndPage 7
ExternalDocumentID oai_doaj_org_article_bdc54c1d61ab4e9fb5d717056b3d2fc8
PMC10563602
10_1530_EC_23_0257
GroupedDBID 53G
5VS
AAFZV
ABLYK
ABSGY
ABSQV
ADBBV
AIPOO
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
BTFSW
DIK
EBS
EE-
F9R
FRJ
GROUPED_DOAJ
GX1
INIJC
KQ8
M~E
OK1
RHF
RPM
TBS
AAKMT
AAYXX
CITATION
H13
M48
PGMZT
7X8
5PM
ID FETCH-LOGICAL-b463t-a6807f179eb536310d9c4d3993f77e177893e11a5f14ebf6b5e11280658f1aa93
IEDL.DBID M48
ISSN 2049-3614
IngestDate Wed Aug 27 01:19:29 EDT 2025
Thu Aug 21 18:35:43 EDT 2025
Thu Jul 10 18:04:38 EDT 2025
Tue Jul 01 02:04:33 EDT 2025
Thu Apr 24 22:57:57 EDT 2025
Tue Oct 03 02:10:32 EDT 2023
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords medullary thyroid cancer
dipeptidyl peptidase IV
incretin system
papillary thyroid cancer
glucagon-like peptide 1 receptor agonist
Language English
License This work is licensed under a Creative Commons Attribution 4.0 International License.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b463t-a6807f179eb536310d9c4d3993f77e177893e11a5f14ebf6b5e11280658f1aa93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ORCID 0000-0001-6521-8578
OpenAccessLink https://doaj.org/article/bdc54c1d61ab4e9fb5d717056b3d2fc8
PMID 37656509
PQID 2860401558
PQPubID 23479
PageCount 7
ParticipantIDs doaj_primary_oai_doaj_org_article_bdc54c1d61ab4e9fb5d717056b3d2fc8
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10563602
proquest_miscellaneous_2860401558
crossref_citationtrail_10_1530_EC_23_0257
crossref_primary_10_1530_EC_23_0257
bioscientifica_primary_10_1530_EC_23_0257
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-11-01
PublicationDateYYYYMMDD 2023-11-01
PublicationDate_xml – month: 11
  year: 2023
  text: 2023-11-01
  day: 01
PublicationDecade 2020
PublicationPlace Bristol
PublicationPlace_xml – name: Bristol
PublicationTitle Endocrine Connections
PublicationYear 2023
Publisher Bioscientifica Ltd
Bioscientifica
Publisher_xml – name: Bioscientifica Ltd
– name: Bioscientifica
References Graaf (bib9) 2016; 68
Parks (bib12) 2010; 362
Bethel (bib35) 2019; 42
Ma (bib53) 2015; 21
He (bib26) 2022; 32
Hernandez (bib45) 2018; 392
Sabouret (bib1) 2023; 71
Chiu (bib14) 2012; 2012
Volpe (bib4) 2022; 14
Liu (bib6) 2022; 13
Gier (bib30) 2012; 97
Gerstein (bib37) 2019; 394
Caparrotta (bib47) 2021; 12
Demetriou (bib61) 2023; 13
Vangoitsenhoven (bib13) 2012; 19
Cui (bib58) 2021; 100
Schmid (bib54) 2015; 16
Gallo (bib33) 2013; 36
Aroda (bib11) 2011; 27
Li (bib62) 2023; 14
Ahn (bib49) 2016; 26
He (bib23) 2020; 37
O'Neill (bib57) 2021; 45
Lisco (bib2) 2022; 13
Nauck (bib34) 2018; 41
Jegerlehner (bib50) 2017; 12
Yang (bib41) 2022; 13
Funch (bib16) 2021; 14
Bloomgarden (bib7) 2010; 2
Hu (bib24) 2021; 44
Sherman (bib31) 2018; 35
Zhang (bib55) 2021; 12
Wharton (bib5) 2022; 134
Kannan (bib15) 2015; 82
Youssef (bib56) 2021; 112
Overbeek (bib27) 2018; 34
Thompson (bib42) 2023; 46
Gerstein (bib46) 2021; 385
Dedhia (bib51) 2022; 5
Marso (bib44) 2016; 375
Rosol (bib10) 2013; 41
Lee (bib25) 2017; 102
Hirai (bib20) 1999; 49
Hu (bib48) 2022; 13
Parola (bib28) 2009
Brubaker (bib8) 2010; 151
Volpe (bib3) 2022; 14
Madsen (bib29) 2012; 153
Bezin (bib40) 2023; 46
Kholová (bib22) 2003; 14
Smits (bib38) 2021; 12
Tanaka (bib21) 1995; 64
Marso (bib43) 2016; 375
bib18
Mali (bib39) 2021; 46
bib19
Burrage (bib59) 2023
bib17
Nianogo (bib52) 2022; 10
Li (bib60) 2023; 10
Hegedüs (bib36) 2018; 41
Franchini (bib63) 2022; 19
Nauck (bib32) 2013; 36
References_xml – ident: bib17
– volume: 153
  start-page: 1538
  year: 2012
  ident: bib29
  article-title: GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation
– volume: 112
  start-page: 105085
  year: 2021
  ident: bib56
  article-title: Obesity and the prevention of thyroid cancer: impact of body mass index and weight change on developing thyroid cancer - Pooled results of 24 million cohorts
– volume: 21
  start-page: 283
  year: 2015
  ident: bib53
  article-title: Obesity and risk of thyroid cancer: evidence from a meta-analysis of 21 observational studies
– volume: 151
  start-page: 1984
  year: 2010
  ident: bib8
  article-title: Minireview: update on incretin biology: focus on glucagon-like peptide-1
– volume: 36
  start-page: S245
  issue: Supplement 2
  year: 2013
  ident: bib32
  article-title: Do GLP-1-based therapies increase cancer risk?
– volume: 46
  start-page: 249
  year: 2023
  ident: bib42
  article-title: Putting GLP-1 RAs and thyroid cancer in context: additional evidence and remaining doubts
– volume: 13
  start-page: 925377
  year: 2022
  ident: bib41
  article-title: GLP-1 receptor agonist-associated tumor adverse events: a real-world study from 2004 to 2021 based on FAERS
– volume: 13
  start-page: 920541
  year: 2022
  ident: bib2
  article-title: Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: a rapid review of randomized controlled trials and meta-analysis
– volume: 2
  start-page: 223
  year: 2010
  ident: bib7
  article-title: Liraglutide and calcitonin
– volume: 12
  start-page: 736972
  year: 2021
  ident: bib55
  article-title: The relationship and gender disparity between thyroid nodules and metabolic syndrome components based on a recent nationwide cross-sectional study and meta-analysis
– volume: 100
  start-page: e26882
  year: 2021
  ident: bib58
  article-title: A meta-analysis of the influence of body mass index on the clinicopathologic progression of papillary thyroid carcinoma
– year: 2023
  ident: bib59
  article-title: Obesity and thyroid cancer risk
– volume: 82
  start-page: 142
  year: 2015
  ident: bib15
  article-title: Should we be concerned about thyroid cancer in patients taking glucagon-like peptide 1 receptor agonists?
– volume: 41
  start-page: 620
  year: 2018
  ident: bib36
  article-title: No evidence of increase in calcitonin concentrations or development of C-cell malignancy in response to liraglutide for UP to 5 years in the LEADER trial
– volume: 14
  start-page: 4673
  year: 2022
  ident: bib4
  article-title: Once-weekly subcutaneous semaglutide improves fatty liver disease in patients with type 2 diabetes: a 52-week prospective real-life study
– volume: 394
  start-page: 121
  year: 2019
  ident: bib37
  article-title: Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
– volume: 34
  start-page: e3004
  year: 2018
  ident: bib27
  article-title: Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: a systematic review and meta-analysis
– volume: 10
  start-page: 1
  year: 2023
  ident: bib60
  article-title: Adipose tissue macrophages: implications for obesity-associated cancer
– volume: 16
  start-page: 1042
  year: 2015
  ident: bib54
  article-title: Adiposity and risk of thyroid cancer: a systematic review and meta-analysis
– volume: 14
  start-page: 2414
  year: 2022
  ident: bib3
  article-title: Once-weekly semaglutide induces an early improvement in body composition in patients with Type 2 diabetes: a 26-week prospective real-life study
– ident: bib18
– volume: 71
  start-page: 1
  year: 2023
  ident: bib1
  article-title: Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis
– volume: 46
  start-page: 99
  year: 2021
  ident: bib39
  article-title: Glucagon-like peptide-1 analogues and thyroid cancer: an analysis of cases reported in the European pharmacovigilance database
– volume: 32
  start-page: 1411
  year: 2022
  ident: bib26
  article-title: Dipeptidyl peptidase-4 stabilizes integrin α4β1 complex to promote thyroid cancer cell metastasis by activating transforming growth factor-beta signaling pathway
– volume: 375
  start-page: 1834
  year: 2016
  ident: bib44
  article-title: Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
– volume: 12
  start-page: 969
  year: 2021
  ident: bib47
  article-title: Glucagon-like peptide 1 receptor agonist (GLP1RA) exposure and outcomes in Type 2 diabetes: a systematic review of population-based observational studies
– volume: 14
  start-page: 23
  year: 2023
  ident: bib62
  article-title: Metabolic syndrome and thyroid Cancer: risk, prognosis, and mechanism
– volume: 45
  start-page: 2805
  year: 2021
  ident: bib57
  article-title: Association of BMI with clinicopathological features of papillary thyroid cancer: a systematic review and meta-analysis
– volume: 68
  start-page: 954
  year: 2016
  ident: bib9
  article-title: Glucagon-like Peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes
– volume: 12
  start-page: e0179387
  year: 2017
  ident: bib50
  article-title: Overdiagnosis and overtreatment of thyroid cancer: a population-based temporal trend study
– volume: 13
  start-page: 1043789
  year: 2022
  ident: bib6
  article-title: Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database
– volume: 14
  start-page: 2619
  year: 2021
  ident: bib16
  article-title: Risk of thyroid cancer associated with use of liraglutide and other antidiabetic drugs in a US Commercially Insured Population
– ident: bib19
– volume: 64
  start-page: 326
  year: 1995
  ident: bib21
  article-title: CD26 (dipeptidyl peptidase IV/DPP IV) as a novel molecular marker for differentiated thyroid carcinoma
– volume: 41
  start-page: 1663
  year: 2018
  ident: bib34
  article-title: Neoplasms reported with liraglutide or placebo in people with Type 2 diabetes: results from the LEADER randomized trial
– volume: 19
  start-page: F77
  year: 2012
  ident: bib13
  article-title: GLP1 and cancer: friend or foe?
– volume: 12
  start-page: 645563
  year: 2021
  ident: bib38
  article-title: Safety of semaglutide
– volume: 19
  start-page: 1116
  year: 2022
  ident: bib63
  article-title: Obesity and thyroid cancer risk: an update
– volume: 10
  start-page: 818816
  year: 2022
  ident: bib52
  article-title: Forecasting obesity and Type 2 diabetes incidence and burden: the ViLA-obesity simulation model
– volume: 46
  start-page: 384
  year: 2023
  ident: bib40
  article-title: GLP-1 receptor agonists and the risk of thyroid cancer
– volume: 42
  start-page: 1075
  year: 2019
  ident: bib35
  article-title: Changes in serum calcitonin concentrations, incidence of medullary thyroid carcinoma, and impact of routine calcitonin concentration monitoring in the exenatide study of cardiovascular event lowering (EXSCEL)
– volume: 35
  start-page: 381
  year: 2018
  ident: bib31
  article-title: No calcitonin change in a person taking dulaglutide diagnosed with pre-existing medullary thyroid cancer
– volume: 392
  start-page: 1519
  year: 2018
  ident: bib45
  article-title: Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
– volume: 26
  start-page: 1535
  year: 2016
  ident: bib49
  article-title: Thyroid cancer screening in South Korea increases detection of papillary cancers with no impact on other subtypes or thyroid cancer mortality
– volume: 362
  start-page: 774
  year: 2010
  ident: bib12
  article-title: Weighing risks and benefits of liraglutide – the FDA's review of a new antidiabetic therapy
– volume: 385
  start-page: 896
  year: 2021
  ident: bib46
  article-title: Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
– volume: 13
  start-page: 927859
  year: 2022
  ident: bib48
  article-title: Use of GLP-1 receptor agonists and occurrence of thyroid disorders: a meta-analysis of randomized controlled trials
– volume: 27
  start-page: 528
  year: 2011
  ident: bib11
  article-title: The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review
– volume: 5
  start-page: e228722
  year: 2022
  ident: bib51
  article-title: Physician perspectives of overdiagnosis and overtreatment of low-risk papillary thyroid cancer in the US
– volume: 36
  start-page: 140
  year: 2013
  ident: bib33
  article-title: Thyroid safety in patients treated with liraglutide
– volume: 13
  start-page: 1292
  year: 2023
  ident: bib61
  article-title: Thyroid nodules and obesity
– volume: 2012
  start-page: 924168
  year: 2012
  ident: bib14
  article-title: A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer
– volume: 134
  start-page: 14
  year: 2022
  ident: bib5
  article-title: Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice
– volume: 41
  start-page: 303
  year: 2013
  ident: bib10
  article-title: On-target effects of GLP-1 receptor agonists on thyroid C-cells in rats and mice
– start-page: 22
  year: 2009
  ident: bib28
– volume: 49
  start-page: 264
  year: 1999
  ident: bib20
  article-title: Dipeptidyl peptidase IV (DPP IV/CD26) staining predicts distant metastasis of ‘benign’ thyroid tumor
– volume: 97
  start-page: 121
  year: 2012
  ident: bib30
  article-title: Glucagon like peptide-1 receptor expression in the human thyroid gland
– volume: 375
  start-page: 311
  year: 2016
  ident: bib43
  article-title: Liraglutide and cardiovascular outcomes in type 2 diabetes
– volume: 44
  start-page: 1609
  year: 2021
  ident: bib24
  article-title: DPP4 gene silencing inhibits proliferation and epithelial-mesenchymal transition of papillary thyroid carcinoma cells through suppression of the MAPK pathway
– volume: 14
  start-page: 27
  year: 2003
  ident: bib22
  article-title: Dipeptidyl peptidase IV expression in thyroid cytology: retrospective histologically confirmed study
– volume: 102
  start-page: 2930
  year: 2017
  ident: bib25
  article-title: Dipeptidyl peptidase IV as a prognostic marker and therapeutic target in papillary thyroid carcinoma
– volume: 37
  start-page: 97
  year: 2020
  ident: bib23
  article-title: The DPP-IV inhibitor saxagliptin promotes the migration and invasion of papillary thyroid carcinoma cells via the NRF2/HO1 pathway
SSID ssj0000816830
Score 2.356985
SecondaryResourceType review_article
Snippet Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have changed considerably the management of type 2 diabetes (T2D). However, recently published data from...
SourceID doaj
pubmedcentral
proquest
crossref
bioscientifica
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 1
SubjectTerms dipeptidyl peptidase iv
glucagon-like peptide 1 receptor agonist
incretin system
medullary thyroid cancer
papillary thyroid cancer
Review
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NS91AEF_Ek4eWViu1tmVLpdBDMJv9SNJL0cezIthTBS-y7Gcb1ETy4qH_fWc2UV5A2ksvIdkdkmVndnYmO_MbQg6cMYzL3GUiGA4XcFBqU4YMsbdElHUlUxb_-Xd1eiHOLuXlWqkvjAkb4YHHiTu03knhmFfMWBHqaKUvEQJGWe6L6FKaL-x5a85U0sFYToLnEx6p5PnhcpEVeGKJ-9Az24xIkSkcZ74lJeT-mbk5D5Zc231OXpDnk9lIj8bhviQbod0mO0ctuMy3v-knmgI50x_yHXL1DSuZ_eza7Ka5DvQO41Z8oIyCcoP7rqfYCexdUdN6Cpzqu8ZTh_zvv9BmRZsBWgPFuvN06KgN1GF2Yw8q-esrcnGy_LE4zaYqCpkVig-ZUVVeRlh3wUquwJrztRMe7ZJYloGVJVgsgTEjIxPBRmUlPKXz1ioyY2q-Szbbrg2vCVXRSxejctYHESvwwx3LObC7LpnxLu6Rz_OZ1XcjZIZGVwO4oJcLXXCNXADah0nXboIjx6oYN0_Sfnyk_dsbj5F3jxQInJ0aQJz0JE76X-K0Rz48cF7DQsPTE9OG7n6li0qBwgPzC2iqmUjMvjjvaZtfCbIbrFgEZive_I8x7pMtLHo_ZkS-JZtDfx_egWk02PdpFfwBFTMPUQ
  priority: 102
  providerName: Directory of Open Access Journals
Title Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
URI http://dx.doi.org/10.1530/EC-23-0257
https://www.proquest.com/docview/2860401558
https://pubmed.ncbi.nlm.nih.gov/PMC10563602
https://doaj.org/article/bdc54c1d61ab4e9fb5d717056b3d2fc8
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3fa9RAEF5qfVFQ1Cq2allRBB-it9nsbiJIqce1RahPHtyLLPuzDZ5Jm0vB_vfO7OWKgSK-hFwyd0d2Zna_ye5-HyFvnTGMi4nLimA4HKBAqYwKGXJvFVFUpUi7-E-_yZN58XUhFltko985NODq1tIO9aTm3fLD78vrA0j4z0m9h08-zqZZjpORQt0hd2FEUpigpwPMTz0yiksk2ZEcAHHGYUgamErHX79PHth6zSGZFuqMB6vE6T8CouNllH-NS0ePyMMBUNLDdQQ8JluheUJ2Dhsopn9d03c0LfFM7853yI9j1Dg7a5tsWf8M9AJXtPhAGYVuD87bjuJNcPyKmsZT8GHX1p46jIzuE61XtO7haqCoSE_7ltpAHe577KCzPnhK5kez79OTbNBXyGwheZ8ZWU5UhIwMVnAJOM9XrvCIWKJSgSkFWCYwZkRkRbBRWgGf0kxsGZkxFX9Gtpu2Cc8JldELF6N01ocillChOzbhEAiVYsa7uEvej1tWX6zJNDQWIeAFPZvqnGv0AthuGl27gagc9TKWt9q-ubH91y9-Qd_dWCCldrrQdmd6yFBtvROFY14yY4tQRSu8Qq4habnPoyt3yeuN5zWkIM6rmCa0VyudlxK6QgBmYFOOQmL0j-M7TX2eyLwB3yJlW773X0_ygtxDvfv1ZsiXZLvvrsIrQEW93U9vE-B4vGD7Kfz_APBUDKM
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Glucagon-like+peptide+1+receptor+agonists+and+thyroid+cancer%3A+is+it+the+time+to+be+concerned%3F&rft.jtitle=Endocrine+Connections&rft.au=Lisco%2C+Giuseppe&rft.au=De+Tullio%2C+Anna&rft.au=Disoteo%2C+Olga&rft.au=Piazzolla%2C+Giuseppina&rft.date=2023-11-01&rft.issn=2049-3614&rft.eissn=2049-3614&rft.volume=12&rft.issue=11&rft_id=info:doi/10.1530%2FEC-23-0257&rft.externalDBID=n%2Fa&rft.externalDocID=10_1530_EC_23_0257
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2049-3614&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2049-3614&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2049-3614&client=summon